Form 4: CG Oncology Director Leonard Post Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 21, 2025, Leonard Post, a director of CG Oncology, exercised a stock option to acquire 1,000 shares of common stock at a price of $0.60 per share.
• On the same day, Post sold 1,000 shares of CG Oncology common stock at a price of $28.00 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 6, 2024.
• Following these transactions, Post directly owns 0 shares of CG Oncology common stock.
• Post also holds 128,077 director stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives and directors to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

CG Oncology, Leonard Post, Stock Option, Form 4, Director, Share Sale, 10b5-1 Plan